Adicet bio reports inducement grants under nasdaq listing rule 5635(c)(4)

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical-stage biotechnology company discovering and developing allogeneic gamma delta car t cell therapies for cancer, today announced it granted inducement awards on august 31, 2022 (the “grant date”) under adicet's 2022 inducement plan as a material inducement to employment to five individuals hired by adicet in august 2022. the employees received, in the aggregate, non-qualified stock options to purchase 114,
ACET Ratings Summary
ACET Quant Ranking